Natalizumab de-escalation to interferon-beta-1b in patients with
Natalizumab de-escalation to interferon-beta-1b in patients with
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Interferon beta-1b
Interferon alpha/beta receptor agonist
What it measured
Main measures
Primary endpoint:
Other measures (1)
Secondary endpoints:
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: · Female or male patients with relapsing-remitting forms of multiple Exclusion: · Patients who have previously entered this study;
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the concept of natalizumab de-escalation to
Loading reviews and guidelines…
Related trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Phase 4 · Stopped early
Stopped
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
- Study to Investigate Pregnancy Outcomes in Female Participants Exposed
Completed
Paper found, not read
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017
Phase 3 · Running, not recruiting
Still running
History
Started
Mar 2013